X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4366) 4366
Book Review (781) 781
Publication (380) 380
Conference Proceeding (359) 359
Dissertation (69) 69
Book Chapter (52) 52
Newspaper Article (17) 17
Book / eBook (6) 6
Trade Publication Article (4) 4
Government Document (3) 3
Magazine Article (2) 2
Data Set (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2666) 2666
humans (2219) 2219
alk (2216) 2216
oncology (1866) 1866
female (1000) 1000
crizotinib (972) 972
anaplastic lymphoma kinase (969) 969
male (940) 940
cancer (816) 816
lung cancer (748) 748
mutation (717) 717
middle aged (683) 683
respiratory system (676) 676
lung neoplasms - genetics (663) 663
immunohistochemistry (650) 650
adult (642) 642
receptor protein-tyrosine kinases - genetics (642) 642
lymphomas (620) 620
pathology (617) 617
chemotherapy (590) 590
egfr (554) 554
animals (535) 535
aged (516) 516
identification (478) 478
adenocarcinoma (471) 471
expression (468) 468
lung neoplasms - drug therapy (460) 460
gene (451) 451
hemic and lymphatic diseases (449) 449
carcinoma, non-small-cell lung - genetics (443) 443
lung neoplasms - pathology (442) 442
tumors (440) 440
lung cancer, non-small cell (427) 427
non-small cell lung cancer (400) 400
carcinoma, non-small-cell lung - drug therapy (386) 386
receptor protein-tyrosine kinases - metabolism (372) 372
genetic aspects (370) 370
nsclc (364) 364
cell lung-cancer (358) 358
gene rearrangement (348) 348
kinases (348) 348
mutations (333) 333
prognosis (333) 333
analysis (322) 322
cell biology (321) 321
lymphoma (318) 318
research (309) 309
neuroblastoma (305) 305
protein-tyrosine kinases - genetics (301) 301
cell line, tumor (300) 300
protein kinase inhibitors - therapeutic use (298) 298
resistance (289) 289
hematology (287) 287
open-label (285) 285
oncogene proteins, fusion - genetics (284) 284
in situ hybridization, fluorescence (282) 282
npm-alk (282) 282
carcinoma, non-small-cell lung - pathology (281) 281
receptor protein-tyrosine kinases (281) 281
non-hodgkins-lymphoma (275) 275
mice (271) 271
aged, 80 and over (269) 269
receptor protein-tyrosine kinases - antagonists & inhibitors (269) 269
eml4-alk fusion gene (267) 267
proteins (263) 263
antineoplastic agents - therapeutic use (259) 259
care and treatment (259) 259
adenocarcinoma - genetics (256) 256
child (247) 247
anaplastic large cell lymphoma (245) 245
biochemistry & molecular biology (245) 245
metastasis (245) 245
ros1 (238) 238
fusion (237) 237
protein-tyrosine kinases - metabolism (233) 233
inflammatory myofibroblastic tumor (228) 228
protein kinase inhibitors - pharmacology (224) 224
receptor tyrosine kinase (224) 224
protein-tyrosine kinase (221) 221
genes (220) 220
pharmacology & pharmacy (220) 220
alectinib (219) 219
article (219) 219
adolescent (214) 214
ceritinib (205) 205
kinase (203) 203
activating mutations (202) 202
diagnosis (202) 202
lung-cancer (200) 200
patients (199) 199
pyridines - therapeutic use (198) 198
tyrosine kinase (197) 197
acquired-resistance (194) 194
health aspects (193) 193
tyrosine (192) 192
pyrazoles - therapeutic use (190) 190
lymphoma, large-cell, anaplastic - pathology (188) 188
alk rearrangement (187) 187
fish (187) 187
hematology, oncology and palliative medicine (186) 186
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (5) 5
Trinity College (John W Graham) - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Online Resources - Online (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4402) 4402
German (267) 267
French (65) 65
Chinese (34) 34
Japanese (26) 26
Korean (15) 15
Russian (11) 11
Spanish (10) 10
Italian (5) 5
Czech (4) 4
Polish (4) 4
Danish (1) 1
Hungarian (1) 1
Persian (1) 1
Slovak (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Histopathology, ISSN 0309-0167, 09/2014, Volume 65, Issue 3, pp. 398 - 407
AimsALKFISH analysis is used as the reference standard to demonstrate ALK rearrangements, which qualify patients with pulmonary adenocarcinomas for therapy... 
ALK | mutations in non‐small‐cell lung cancer | antibody clones | immunohistochemical screening for | EML | rearrangements | FISH | rearrangement | ALK mutations in non-small-cell lung cancer | EML4-ALK rearrangement | Immunohistochemical screening for ALK rearrangements | ALK antibody clones | ALK FISH | immunohistochemical screening for ALK rearrangements | ADENOCARCINOMA | EML4-ALK FUSION GENE | PATHOLOGY | IDENTIFICATION | VARIANT | EGFR | CELL BIOLOGY | CELL LUNG-CANCER | INHIBITION | RECOMMENDATIONS | KIF5B-ALK | MUTATIONS | Predictive Value of Tests | Adenocarcinoma - pathology | Humans | Middle Aged | Receptor Protein-Tyrosine Kinases - immunology | Lung Neoplasms - pathology | Male | Adult | Female | Adenocarcinoma - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Rabbits | Antibodies, Monoclonal, Murine-Derived | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Adenocarcinoma - enzymology | Antibodies, Monoclonal | Receptor Protein-Tyrosine Kinases - metabolism | Immunohistochemistry - methods | Animals | Receptor Protein-Tyrosine Kinases - genetics | Gene Rearrangement | Aged | Mice | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | In Situ Hybridization, Fluorescence - methods | Immunohistochemistry | Viral antibodies | Cloning | Antibodies | Animal genetic engineering | Medical tests | Diagnosis | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
LUNG CANCER, ISSN 0169-5002, 01/2016, Volume 91, pp. 70 - 72
Many acquired resistant mutations to the anaplastic lymphoma kinase (ALK) gene have been identified during treatment of ALK-rearranged non-small cell lung... 
Comprehensive genomic profiling | Alectinib | Acquired resistance | ALK inhibitor | ONCOLOGY | RESPIRATORY SYSTEM | ALK I1171S mutation | ALK-positive lung cancer | NSCLC PATIENTS | ALK F1174V mutation
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 11/2018, Volume 19, Issue 11, pp. 962 - 966
The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. More than... 
fusion partner gene | crizotinib | CMTR1 | ALK-tyrosine kinase inhibitor (TKI) | ALK-rearranged NSCLC | Anaplastic lymphoma kinase (ALK) | VARIANT | CHEMOTHERAPY | LUNG-CANCER | GENE | ONCOLOGY | KIF5B-ALK | CANCER STATISTICS
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 08/2019, Volume 43, Issue 8, pp. 1152 - 1154
Journal Article
Journal Article
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 04/2019, Volume 35, Issue 4, pp. 569 - 576
Objective: Brigatinib, ceritinib, and alectinib are approved to treat crizotinib-refractory anaplastic lymphoma kinase-positive (ALK+) non-small cell lung... 
Brigatinib | ALK + NSCLC | Alectinib | Ceritinib | Indirect comparison | ALK + NSCLC | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | ALK plus NSCLC | SAFETY | OPEN-LABEL | CHEMOTHERAPY
Journal Article
American Journal of Surgical Pathology, ISSN 0147-5185, 01/2017, Volume 41, Issue 1, pp. 25 - 38
Journal Article
Journal Article
Journal Article
Journal Article
Frontiers in Oncology, 2014, Volume 4, pp. 1 - 26
Lung cancer remains the most lethal malignancy in the world. Despite improvements in surgical treatment, systemic therapy and radiotherapy, the 5-year survival... 
ALK | Lung Adenocarcinoma | ROS-1 | Met | biomarkers | EGFR
Journal Article
The Oncologist, ISSN 1083-7159, 04/2019, Volume 24, Issue 4, pp. 449 - 454
Carcinoma of unknown primary is defined as a malignant tumor for which the primary site of origin cannot be determined, making targeted treatment impossible.... 
fusion | ALK | EML4‐ALK | Carcinoma of unknown primary | inhibitor | Next‐generation sequencing | EML4-ALK fusion | Next-generation sequencing | ALK inhibitor | PRIMARY SITE | TISSUE | IDENTIFICATION | CANCER | FEATURES | TRIAL | THERAPY | GENE | ONCOLOGY
Journal Article
Translational Cancer Research, ISSN 2218-676X, 01/2019, Volume 8, Issue S1, pp. S48 - S54
Lung cancer still represents the leading cause of cancer-related mortality. However, the recent advent of tyrosine kinase inhibitors (TKI), pioneering drugs... 
ALK inhibitors | ALK tyrosine kinase inhibitor (ALK-TKI) | Non-small cell lung cancer (NSCLC) | Anaplastic lymphoma kinase (ALK) | ONCOLOGY | CERITINIB | anaplastic lymphoma kinase (ALK) | ALECTINIB | CRIZOTINIB | CHEMOTHERAPY
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2019, Volume 144, Issue 1, pp. 190 - 199
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.